DK1948180T3 - Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer - Google Patents
Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorerInfo
- Publication number
- DK1948180T3 DK1948180T3 DK06819380.4T DK06819380T DK1948180T3 DK 1948180 T3 DK1948180 T3 DK 1948180T3 DK 06819380 T DK06819380 T DK 06819380T DK 1948180 T3 DK1948180 T3 DK 1948180T3
- Authority
- DK
- Denmark
- Prior art keywords
- combination treatment
- cancer including
- her2 inhibitors
- including egfr
- egfr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05110669 | 2005-11-11 | ||
| PCT/EP2006/068314 WO2007054551A1 (en) | 2005-11-11 | 2006-11-09 | Combination treatment of cancer comprising egfr/her2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1948180T3 true DK1948180T3 (da) | 2013-05-27 |
Family
ID=37658836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06819380.4T DK1948180T3 (da) | 2005-11-11 | 2006-11-09 | Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20090306101A1 (da) |
| EP (2) | EP2340837B1 (da) |
| JP (1) | JP2009515852A (da) |
| CA (1) | CA2629249C (da) |
| CY (1) | CY1114040T1 (da) |
| DK (1) | DK1948180T3 (da) |
| ES (1) | ES2412879T3 (da) |
| PL (1) | PL1948180T3 (da) |
| PT (1) | PT1948180E (da) |
| SI (1) | SI1948180T1 (da) |
| WO (1) | WO2007054551A1 (da) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MEP45508A (en) | 1999-06-21 | 2011-02-10 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof |
| US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| PT1392359E (pt) | 2001-05-11 | 2010-01-27 | Ludwig Inst For Cancer Res Ltd | Proteínas de ligação específica e suas utilizações |
| DE10221018A1 (de) * | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| DE10349113A1 (de) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| KR101313702B1 (ko) | 2005-02-03 | 2013-10-04 | 와이어쓰 | 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물 |
| TW200803892A (en) | 2005-11-04 | 2008-01-16 | Wyeth Corp | Antineoplastic combinations with MTOR inhibitor, herceptin, and/or HKI-272 |
| WO2007054550A1 (en) * | 2005-11-11 | 2007-05-18 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
| WO2007057399A2 (en) * | 2005-11-15 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Treatment of cancer with indole derivatives |
| EP1981863B1 (en) | 2006-01-26 | 2012-10-10 | Boehringer Ingelheim International GmbH | Process for preparing aminocrotonylamino-substituted quinazoline derivatives |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| NZ576065A (en) * | 2006-09-18 | 2011-12-22 | Boehringer Ingelheim Int | Method for treating cancer harboring egfr mutations |
| MX338185B (es) | 2007-01-25 | 2016-04-05 | Dana Farber Cancer Inst Inc | Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante. |
| AU2008227123B2 (en) | 2007-03-15 | 2014-03-27 | Ludwig Institute For Cancer Research Ltd. | Treatment method using EGFR antibodies and src inhibitors and related formulations |
| WO2009019205A1 (en) * | 2007-08-03 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Crystalline form of a dihydropteridione derivative |
| JP5532486B2 (ja) | 2007-08-14 | 2014-06-25 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Ｅｇｆ受容体を標的とするモノクローナル抗体１７５ならびにその誘導体および用途 |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| WO2009138780A2 (en) * | 2008-05-13 | 2009-11-19 | Astrazeneca Ab | Therapeutic treatment - 355 |
| US20170065529A1 (en) | 2015-09-09 | 2017-03-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical dosage form for immediate release of an indolinone derivative |
| PL2299987T3 (pl) * | 2008-06-06 | 2018-08-31 | Boehringer Ingelheim International Gmbh | Farmaceutyczna postać dawkowania w formie kapsułki zawierająca formulację zwiesiny pochodnej indolinonu |
| UY31867A (es) * | 2008-06-06 | 2010-01-29 | Boehringer Ingelheim Int | Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992 |
| UA107560C2 (uk) | 2008-06-06 | 2015-01-26 | Фармацевтична лікарська форма для негайного вивільнення похідної індолінону | |
| AU2015227503B2 (en) * | 2008-06-06 | 2017-02-23 | Boehringer Ingelheim International Gmbh | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
| DK2310011T3 (da) | 2008-06-17 | 2013-10-14 | Wyeth Llc | Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin |
| KR101434009B1 (ko) | 2008-08-04 | 2014-08-25 | 와이어쓰 엘엘씨 | 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물 |
| JP5781934B2 (ja) | 2008-11-10 | 2015-09-24 | ナショナル ヘルス リサーチ インスティテューツ | チロシンキナーゼ阻害剤としての融合２環および３環ピリミジン化合物 |
| US20120157472A1 (en) * | 2009-01-14 | 2012-06-21 | Boehringer Ingelheim International Gmbh | Method for treating colorectal cancer |
| US9073916B2 (en) * | 2009-03-11 | 2015-07-07 | Auckland Uniservices Limited | Prodrug forms of kinase inhibitors and their use in therapy |
| US9211291B2 (en) | 2009-04-06 | 2015-12-15 | Wyeth Llc | Treatment regimen utilizing neratinib for breast cancer |
| UY32560A (es) | 2009-04-29 | 2010-11-30 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| EP2429520A1 (en) | 2009-05-14 | 2012-03-21 | Boehringer Ingelheim International GmbH | New combination therapy in treatment of oncological and fibrotic diseases |
| EP2429527A1 (en) * | 2009-05-14 | 2012-03-21 | Boehringer Ingelheim International GmbH | New combination therapy in treatment of cancer and fibrotic diseases |
| WO2010133629A1 (en) * | 2009-05-19 | 2010-11-25 | Grindeks, A Joint Stock Company | Stable pharmaceutical composition of fludarabine phosphate |
| PT2451445T (pt) | 2009-07-06 | 2019-07-10 | Boehringer Ingelheim Int | Processo para secagem de bibw2992, dos seus sais e de formulações farmacêuticas sólidas compreendendo este ingrediente ativo |
| MX336332B (es) * | 2009-09-02 | 2016-01-15 | Auckland Uniservices Ltd | Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia. |
| CA2780332C (en) * | 2009-11-09 | 2018-01-30 | Wyeth Llc | Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea |
| DK2498756T4 (da) * | 2009-11-09 | 2023-03-20 | Wyeth Llc | Tabletformuleringer af neratinibmaleat |
| EP2509592A1 (en) * | 2009-12-07 | 2012-10-17 | Boehringer Ingelheim International GmbH | Bibw 2992 for use in the treatment of triple negative breast cancer |
| JP2013520681A (ja) * | 2010-02-24 | 2013-06-06 | バイオデシックス・インコーポレイテッド | 質量スペクトル分析を用いた、治療薬投与のための癌患者のセレクション |
| US20130096123A1 (en) * | 2010-04-14 | 2013-04-18 | Eupharma Pty Ltd | Radiation sensitiser compositions |
| US20120107304A1 (en) | 2010-04-27 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Combination therapy in treatment of oncological and fibrotic diseases |
| NO2608792T3 (da) | 2010-08-26 | 2018-03-10 | ||
| US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| CN103648500B (zh) * | 2011-03-17 | 2016-05-04 | 宾夕法尼亚大学理事会 | 双功能酶制钳型分子的方法和用途 |
| US9295676B2 (en) | 2011-03-17 | 2016-03-29 | The Trustees Of The University Of Pennsylvania | Mutation mimicking compounds that bind to the kinase domain of EGFR |
| WO2012135848A2 (en) * | 2011-04-01 | 2012-10-04 | Scott & White Healthcare | Melatonin-based treatment and diagnosis of bile duct disease |
| CA2832504C (en) | 2011-05-04 | 2019-10-01 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| US8828391B2 (en) | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| WO2013135176A1 (zh) * | 2012-03-16 | 2013-09-19 | 苏州迈泰生物技术有限公司 | 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途 |
| AU2013204563B2 (en) | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| US9371555B2 (en) | 2012-06-01 | 2016-06-21 | Concordia Laboratories Inc. | Lighting systems and methods of using lighting systems for in vitro potency assay for photofrin |
| US20150368230A1 (en) | 2013-02-01 | 2015-12-24 | Boehringer Ingelheim International Gmbh | Radiolabeled quinazoline derivatives |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| TWI609012B (zh) | 2013-04-28 | 2017-12-21 | 廣東東陽光藥業有限公司 | 氨基喹唑啉類衍生物及其鹽和使用方法 |
| US20150031699A1 (en) | 2013-07-26 | 2015-01-29 | Boehringer Ingelheim International Gmbh | Treatment of myelodysplastic syndrome |
| US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
| WO2015175632A1 (en) * | 2014-05-13 | 2015-11-19 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| KR102628356B1 (ko) * | 2014-06-19 | 2024-01-24 | 다케다 야쿠힌 고교 가부시키가이샤 | 키나제 저해를 위한 헤테로아릴 화합물 |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
| CN105801568B (zh) | 2015-01-15 | 2019-07-30 | 杭州普晒医药科技有限公司 | 阿法替尼一马来酸盐晶型及其制备方法和药物组合物 |
| WO2017136770A1 (en) * | 2016-02-05 | 2017-08-10 | Merrimack Pharmaceuticals, Inc. | Treatment of her2-intermediate cancer |
| MX2020012063A (es) | 2018-05-14 | 2021-04-13 | Takeda Pharmaceuticals Co | Sales farmaceuticas de derivados de pirimidina y metodo de tratamiento de trastornos. |
| MX2021006557A (es) | 2018-12-04 | 2021-09-08 | Der Yang Tien | Estereocomplejos para la administración de agentes anticancerígenos. |
| EP4006014B1 (en) * | 2019-07-26 | 2023-10-11 | China Resources Pharmaceutical Holdings Company Limited | Pyrimidine compound acting on egfr and erbb2 |
| CN110522909B (zh) * | 2019-09-30 | 2024-02-20 | 安徽省立医院 | 一种协同增强抗her2阳性肿瘤效果的药物组合 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4128089A (en) * | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| MEP45508A (en) * | 1999-06-21 | 2011-02-10 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof |
| US7019012B2 (en) * | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| DE10063435A1 (de) | 2000-12-20 | 2002-07-04 | Boehringer Ingelheim Pharma | Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE10221018A1 (de) * | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
| US20030225079A1 (en) * | 2002-05-11 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy |
| DE10307165A1 (de) | 2003-02-20 | 2004-09-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung |
| RS52386B (sr) | 2003-02-26 | 2013-02-28 | Boehringer Ingelheim Pharma Gmbh & Co.Kg. | Dihidropteridinoni, postupak za njihovo pripremanje i njihova primena kao leka |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| DE10349113A1 (de) * | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
| EP2439285B1 (en) * | 2004-03-31 | 2019-05-08 | The General Hospital Corporation | Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments |
| US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| KR101313702B1 (ko) * | 2005-02-03 | 2013-10-04 | 와이어쓰 | 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물 |
| WO2007054550A1 (en) * | 2005-11-11 | 2007-05-18 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
| EP1981863B1 (en) * | 2006-01-26 | 2012-10-10 | Boehringer Ingelheim International GmbH | Process for preparing aminocrotonylamino-substituted quinazoline derivatives |
| NZ576065A (en) * | 2006-09-18 | 2011-12-22 | Boehringer Ingelheim Int | Method for treating cancer harboring egfr mutations |
| UY31867A (es) * | 2008-06-06 | 2010-01-29 | Boehringer Ingelheim Int | Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992 |
| US20120157472A1 (en) * | 2009-01-14 | 2012-06-21 | Boehringer Ingelheim International Gmbh | Method for treating colorectal cancer |
| PT2451445T (pt) * | 2009-07-06 | 2019-07-10 | Boehringer Ingelheim Int | Processo para secagem de bibw2992, dos seus sais e de formulações farmacêuticas sólidas compreendendo este ingrediente ativo |
| EP2509592A1 (en) * | 2009-12-07 | 2012-10-17 | Boehringer Ingelheim International GmbH | Bibw 2992 for use in the treatment of triple negative breast cancer |
| US8828391B2 (en) * | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
-
2006
- 2006-11-09 DK DK06819380.4T patent/DK1948180T3/da active
- 2006-11-09 ES ES06819380T patent/ES2412879T3/es active Active
- 2006-11-09 SI SI200631584T patent/SI1948180T1/sl unknown
- 2006-11-09 CA CA2629249A patent/CA2629249C/en active Active
- 2006-11-09 EP EP11155582.7A patent/EP2340837B1/en active Active
- 2006-11-09 PT PT68193804T patent/PT1948180E/pt unknown
- 2006-11-09 PL PL06819380T patent/PL1948180T3/pl unknown
- 2006-11-09 EP EP06819380A patent/EP1948180B1/en active Active
- 2006-11-09 US US12/093,322 patent/US20090306101A1/en not_active Abandoned
- 2006-11-09 WO PCT/EP2006/068314 patent/WO2007054551A1/en not_active Ceased
- 2006-11-09 JP JP2008539441A patent/JP2009515852A/ja active Pending
-
2013
- 2013-06-07 CY CY20131100455T patent/CY1114040T1/el unknown
-
2014
- 2014-01-22 US US14/160,700 patent/US20140199298A1/en not_active Abandoned
-
2017
- 2017-12-01 US US15/828,644 patent/US20180086744A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SI1948180T1 (sl) | 2013-06-28 |
| PL1948180T3 (pl) | 2013-09-30 |
| US20180086744A1 (en) | 2018-03-29 |
| CA2629249C (en) | 2015-05-05 |
| EP2340837B1 (en) | 2017-03-15 |
| EP1948180B1 (en) | 2013-03-13 |
| EP1948180A1 (en) | 2008-07-30 |
| EP2340837A1 (en) | 2011-07-06 |
| ES2412879T3 (es) | 2013-07-12 |
| US20090306101A1 (en) | 2009-12-10 |
| CA2629249A1 (en) | 2007-05-18 |
| CY1114040T1 (el) | 2016-07-27 |
| WO2007054551A1 (en) | 2007-05-18 |
| JP2009515852A (ja) | 2009-04-16 |
| PT1948180E (pt) | 2013-05-10 |
| US20140199298A1 (en) | 2014-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1948180T3 (da) | Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer | |
| NO20200775A1 (no) | Fremgangsmåter og sammensetninger for behandling av kreft | |
| IL196470A (en) | Antagonist antibody for the treatment of cancer | |
| LTPA2017004I1 (lt) | Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės-delta inhibitoriai | |
| IL197217B (en) | Novel anti-cd38 antibodies for the treatment of cancer | |
| DK3289876T3 (da) | Forbindelser til behandling af cancer | |
| DK2195015T3 (da) | Sammensætning til behandling af prostatacancer | |
| DK2155188T3 (da) | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft | |
| BRPI0810206A2 (pt) | Método de tratar câncer | |
| DK1948693T3 (da) | Monoklonale antistoffer mod claudin-18 til behandling af cancer | |
| EP1766068A4 (en) | EGFR Mutations | |
| DK1874821T3 (da) | Kombination af antistoffer med glykokortikoider til behandling af kræft | |
| DK2121139T3 (da) | Formulations for cancer treatment | |
| PT2115472E (pt) | Biomarcadores de cancro | |
| DK1755671T3 (da) | Terapi af platinresistent cancer | |
| DK1781604T3 (da) | Bis(thio-hydrazid-amid)-salte til behandling af cancere | |
| DK1960370T3 (da) | Pyridazinonderivater til tumorbehandling | |
| BRPI0821779A2 (pt) | tratamento terapêutico de câncer | |
| IS8125A (is) | Kínasólínafleiður til að meðhöndla krabbamein | |
| DK1868579T3 (da) | Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer | |
| DK1716119T3 (da) | Analoger af benzoquinonholdige ansamyciner til behandling af cancer | |
| PL1937244T3 (pl) | Leczenie nowotworu specyficznymi agonistami rxr | |
| BRPI0912683A2 (pt) | tratamento de tumores metastáticos | |
| ATE413389T1 (de) | Chinazolinderivate | |
| HUE036490T2 (hu) | Tumorok kezelése anti-L1 antitest alkalmazásával |